Literature DB >> 17272973

Fluoxetine for persistent developmental stuttering.

Amardeep Kumar1, Sabish Balan.   

Abstract

Stuttering is a disturbance in the normal fluency and time patterning of speech. Developmental stuttering (DS), with or without associated psychiatric illness, is the most common form and includes all cases with gradual onset in childhood that are not the result of acquired brain damage. Persistent developmental stuttering (PDS) is DS that has not undergone spontaneous or speech therapy-induced remission. Adults in speech therapy behavioral programs will often show regression and even total relapse if they stop practicing. This case report deals with a patient of PDS who responded significantly to treatment with fluoxetine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17272973     DOI: 10.1097/01.wnf.0000240950.18821.19

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  5 in total

1.  Research on antidepressants in India.

Authors:  Ajit Avasthi; Sandeep Grover; Munish Aggarwal
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

2.  Green tea consumption and the management of adrenal stress hormones in adolescents who stutter.

Authors:  Abdulaziz Almudhi; Sami A Gabr
Journal:  Biomed Rep       Date:  2022-02-24

3.  Olanzapine versus haloperidol: which can control stuttering better?

Authors:  Vahid Shaygannejad; Seyed Ahmadreza Khatoonabadi; Bijan Shafiei; Majid Ghasemi; Farzad Fatehi; Rokhsareh Meamar; Leila Dehghani
Journal:  Int J Prev Med       Date:  2013-05

4.  Anterior capsulotomy improves persistent developmental stuttering with a psychiatric disorder: a case report and literature review.

Authors:  Shizhen Zhang; Peng Li; Zhujun Zhang; Wei Wang
Journal:  Neuropsychiatr Dis Treat       Date:  2014-04-01       Impact factor: 2.570

5.  Altered Modulation of Silent Period in Tongue Motor Cortex of Persistent Developmental Stuttering in Relation to Stuttering Severity.

Authors:  Pierpaolo Busan; Giovanni Del Ben; Simona Bernardini; Giulia Natarelli; Marco Bencich; Fabrizio Monti; Paolo Manganotti; Piero Paolo Battaglini
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.